

# Friedrich Grimmer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1785061/publications.pdf>

Version: 2024-02-01

56  
papers

3,597  
citations

172457

29  
h-index

155660

55  
g-index

60  
all docs

60  
docs citations

60  
times ranked

4608  
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel non-invasive and echocardiography-derived method for quantification of right ventricular pressure–volume loops. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 498-507.	1.2	22
2	Myeloid-cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice. <i>European Respiratory Journal</i> , 2022, 59, 2101153.	6.7	13
3	Unmasking right ventricular-arterial uncoupling during fluid challenge in pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 345-355.	0.6	12
4	Severe organising pneumonia following COVID-19. <i>Thorax</i> , 2021, 76, 201-204.	5.6	68
5	Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. <i>EClinicalMedicine</i> , 2021, 34, 100822.	7.1	22
6	Right ventricular pressure-volume loop shape and systolic pressure change in pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L715-L725.	2.9	21
7	The effect of long-term doxycycline treatment in a mouse model of cigarette smoke-induced emphysema and pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L903-L915.	2.9	9
8	TRAF2 Is a Novel Ubiquitin E3 Ligase for the Na,K-ATPase $\beta$ -Subunit That Drives Alveolar Epithelial Dysfunction in Hypercapnia. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 689983.	3.7	2
9	Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. <i>Communications Biology</i> , 2021, 4, 1002.	4.4	3
10	Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression. <i>Cancers</i> , 2021, 13, 4127.	3.7	7
11	Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome. <i>European Respiratory Review</i> , 2021, 30, 210059.	7.1	16
12	Adenylate Kinase 4–A Key Regulator of Proliferation and Metabolic Shift in Human Pulmonary Arterial Smooth Muscle Cells via Akt and HIF-1 $\alpha$ Signaling Pathways. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10371.	4.1	11
13	Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. <i>Cancers</i> , 2021, 13, 208.	3.7	10
14	Epithelial cell plasticity defines heterogeneity in lung cancer. <i>Cellular Signalling</i> , 2020, 65, 109463.	3.6	17
15	Metabolism in tumour-associated macrophages: a quid pro quo with the tumour microenvironment. <i>European Respiratory Review</i> , 2020, 29, 200134.	7.1	25
16	Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non–Small Cell Lung Carcinoma. <i>Cancer Research</i> , 2020, 80, 4414-4425.	0.9	109
17	Fibroblast Growth Factor–14 Acts as Tumor Suppressor in Lung Adenocarcinomas. <i>Cells</i> , 2020, 9, 1755.	4.1	12
18	Metastasis-Associated Protein 2 Represses NF- $\kappa$ B to Reduce Lung Tumor Growth and Inflammation. <i>Cancer Research</i> , 2020, 80, 4199-4211.	0.9	9

#	ARTICLE	IF	CITATIONS
19	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. <i>Nature Metabolism</i> , 2020, 2, 532-546.	11.9	23
20	Reprogramming of tumor-associated macrophages by targeting $\beta^2$ -catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer. <i>Science Advances</i> , 2020, 6, eaaz6105.	10.3	110
21	Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk. <i>Frontiers in Oncology</i> , 2020, 10, 324.	2.8	76
22	Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 3560-3575.	8.2	103
23	A RASSF1A-HIF1 $\alpha$ loop drives Warburg effect in cancer and pulmonary hypertension. <i>Nature Communications</i> , 2019, 10, 2130.	12.8	77
24	Evidence for the Fucoidan/P-Selectin Axis as a Therapeutic Target in Hypoxia-induced Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1407-1420.	5.6	39
25	FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. <i>EMBO Molecular Medicine</i> , 2018, 10, 276-293.	6.9	85
26	Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1235-1244.	0.6	26
27	The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 957-967.	0.6	221
28	Mitochondrial Complex IV Subunit 4 Isoform 2 Is Essential for Acute Pulmonary Oxygen Sensing. <i>Circulation Research</i> , 2017, 121, 424-438.	4.5	90
29	Lipoteichoic acids from <i>Staphylococcus aureus</i> stimulate proliferation of human non-small-cell lung cancer cells in vitro. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 799-809.	4.2	33
30	Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	69
31	Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension. <i>Clinical Research in Cardiology</i> , 2017, 106, 174-182.	3.3	16
32	Selexipag for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1825-1834.	1.8	3
33	Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma. <i>PLoS ONE</i> , 2015, 10, e0139073.	2.5	101
34	Macrophage and Cancer Cell Cross-talk via CCR2 and CX3CR1 Is a Fundamental Mechanism Driving Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 437-447.	5.6	186
35	Stimulation of Soluble Guanylate Cyclase Prevents Cigarette Smoke-induced Pulmonary Hypertension and Emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1359-1373.	5.6	80
36	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. <i>Nature Medicine</i> , 2014, 20, 1289-1300.	30.7	233

#	ARTICLE	IF	CITATIONS
37	Novel and Emerging Therapies for Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 394-400.	5.6	75
38	Classical Transient Receptor Potential Channel 1 in Hypoxia-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1451-1459.	5.6	77
39	Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice. Cell, 2011, 147, 293-305.	28.9	293
40	Role of Epidermal Growth Factor Inhibition in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 158-167.	5.6	118
41	Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S108-S117.	2.8	62
42	NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L638-L645.	2.9	59
43	Alveolar epithelial barrier functions in ventilated perfused rabbit lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L896-L904.	2.9	23
44	Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L1361-L1368.	2.9	37
45	Coaerosolization of Phosphodiesterase Inhibitors Markedly Enhances the Pulmonary Vasodilatory Response to Inhaled Iloprost in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1694-1700.	5.6	54
46	Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 219-225.	2.9	22
47	The PDE inhibitor zaprinast enhances NO-mediated protection against vascular leakage in reperfused lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L496-L502.	2.9	12
48	Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L25-L35.	2.9	171
49	Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived $H_2O_2$ ?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L683-L690.	2.9	87
50	PAF-induced synthesis of tetraenoic and pentaenoic leukotrienes in the isolated rabbit lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 278, L268-L275.	2.9	18
51	Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 276, L90-L95.	2.9	43
52	Low-dose Systemic Phosphodiesterase Inhibitors Amplify the Pulmonary Vasodilatory Response to Inhaled Prostacyclin in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1500-1506.	5.6	73
53	Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 600-607.	5.6	369
54	Use of fish oil to prevent graft rejection. Proceedings of the Nutrition Society, 1998, 57, 577-585.	1.0	8

#	ARTICLE	IF	CITATIONS
55	Nitro blue tetrazolium inhibits but does not mimic hypoxic vasoconstriction in isolated rabbit lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1998, 274, L721-L727.	2.9	24
56	Hypoxic Pulmonary Vasoconstriction-Triggered by an Increase in Reactive Oxygen Species?. Novartis Foundation Symposium, 0, , 196-213.	1.1	12